Entropy Technologies LP Invests $445,000 in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Entropy Technologies LP bought a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 13,960 shares of the company’s stock, valued at approximately $445,000.

A number of other institutional investors have also modified their holdings of APLS. Wolverine Asset Management LLC bought a new position in Apellis Pharmaceuticals during the third quarter worth $27,000. True Wealth Design LLC bought a new position in shares of Apellis Pharmaceuticals in the 3rd quarter worth about $27,000. Capital Performance Advisors LLP bought a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at about $56,000. KBC Group NV lifted its holdings in Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after acquiring an additional 679 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after acquiring an additional 781 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Cedric Francois sold 13,551 shares of the company’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $412,356.93. Following the completion of the transaction, the chief executive officer now directly owns 418,519 shares in the company, valued at $12,735,533.17. This represents a 3.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Caroline Baumal sold 2,816 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $33.81, for a total transaction of $95,208.96. Following the transaction, the insider now directly owns 55,560 shares of the company’s stock, valued at $1,878,483.60. This represents a 4.82 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 60,365 shares of company stock valued at $1,810,479 over the last quarter. Insiders own 6.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on APLS. The Goldman Sachs Group cut Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 target price on the stock. in a research note on Tuesday, December 17th. Evercore ISI raised shares of Apellis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, October 31st. Morgan Stanley started coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price objective for the company. Citigroup decreased their price target on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Piper Sandler dropped their price objective on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Apellis Pharmaceuticals Stock Down 0.1 %

APLS stock opened at $28.51 on Thursday. The firm has a market cap of $3.55 billion, a PE ratio of -14.04 and a beta of 0.96. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90. The company has a fifty day simple moving average of $31.45 and a 200 day simple moving average of $32.30. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).